Summary & Overview
CPT 87811: COVID-19 Antigen Detection by Immunoassay
CPT code 87811 represents a laboratory test for the detection of SARS‑CoV‑2 antigens using immunoassay with direct optical observation. This code is central to COVID-19 diagnostic efforts, enabling rapid identification of the virus in office-based settings. The test is widely used across the United States, playing a critical role in public health response and clinical management of COVID-19 cases.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for services billed under CPT code 87811. This publication offers an overview of payer coverage, clinical context, and policy updates relevant to this laboratory service. Readers will gain insights into coding benchmarks, payer policies, and the clinical importance of rapid antigen testing for COVID-19.
The article also highlights related codes and diagnoses commonly associated with COVID-19 testing, offering a comprehensive view of the billing and clinical landscape. Key updates and trends in laboratory testing for respiratory infections are discussed, providing valuable information for healthcare professionals, billing specialists, and policy analysts.
CPT Code Overview
CPT code 87811 is used for the detection of infectious agent antigens by immunoassay with direct optical (visual) observation, specifically targeting severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus responsible for Coronavirus disease (COVID‑19). This laboratory service is typically performed in an office setting (Place of Service 11), providing rapid and accessible testing for COVID-19. The code is essential for identifying active infections and supporting timely clinical decision-making in outpatient environments.
Clinical & Coding Specifications
Clinical Context
A patient presents to a family medicine or internal medicine office with symptoms such as cough, fever, and other respiratory manifestations. The clinician suspects a viral respiratory infection, including possible COVID-19 or influenza. A nasal or throat swab is collected and a rapid antigen test for SARS-CoV-2 is performed using a CLIA-waived immunoassay with direct optical observation. The test is conducted onsite in the office laboratory, and results are available during the patient visit to guide clinical management.
Coding Specifications
- Modifier
QW: Indicates that the test is CLIA-waived and can be performed in a laboratory with a CLIA Certificate of Waiver.
| Modifier Code | Description |
|---|---|
QW | CLIA waived test |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
291U00000X | Clinical Medical Laboratory |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
-
Specialties Represented:
- Clinical Medical Laboratory: Laboratory professionals performing diagnostic tests.
- Family Medicine Physician: Primary care providers managing acute and chronic illnesses.
- Internal Medicine Physician: Providers specializing in adult medicine and complex conditions.
Related Diagnoses
-
J10.1: Influenza with other respiratory manifestations, seasonal influenza virus identified- Relevant when a patient presents with symptoms and laboratory confirmation of seasonal influenza.
-
J11.1: Influenza with other respiratory manifestations, virus not identified- Used when influenza is suspected based on symptoms, but laboratory confirmation is not available.
-
J09.X2: Influenza due to identified novel influenza A virus with other respiratory manifestations- Applies when a novel influenza A virus is identified in a patient with respiratory symptoms.
-
J06.9: Acute upper respiratory infection, unspecified- Used for patients with acute respiratory symptoms where the specific cause is not determined.
-
R05: Cough- Indicates the presence of cough, a common symptom prompting respiratory viral testing.
Related CPT Codes
87428: Infectious agent antigen detection by immunoassay technique (e.g., enzyme immunoassay [EIA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS‑CoV, SARS‑CoV‑2 [COVID‑19]) and influenza virus types A and B
Clinical Relationship:
87428is used when testing for both SARS-CoV-2 and influenza A/B antigens in a single assay. It is related to87811as both are used for respiratory viral antigen detection, but87428covers a broader panel.87428may be used as an alternative to87811when clinical suspicion includes both COVID-19 and influenza, or as a companion code if both tests are performed.
National Reimbursement Benchmarks
National mean rates for CPT code 87811 show that BUCA (average commercial) payers reimburse at $41.09, while individual commercial payers such as Aetna and UnitedHealth Group are slightly higher, at $43.42 and $43.90 respectively. Blue Cross Blue Shield and Cigna are somewhat lower, with mean rates of $37.11 and $41.13. Medicare rates are not available in the input.
Rate dispersion varies significantly across payers. Aetna has the tightest range, with its 75th and 25th percentiles both at $41.00, indicating minimal variation. Cigna displays the widest spread, with a difference of $31.33 between its 75th percentile ($53.33) and 25th percentile ($22.00). Blue Cross Blue Shield, UnitedHealth Group, and BUCA show moderate dispersion, with ranges of $12.00, $17.50, and $13.10 respectively.
The table and chart below present the full breakdown of national benchmarks for CPT code 87811 by payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.